tiprankstipranks
Advertisement
Advertisement
Neutral Stance Maintained as Madrigal’s Growth Prospects Tempered; Price Target Trimmed from $553 to $543
PremiumRatingsNeutral Stance Maintained as Madrigal’s Growth Prospects Tempered; Price Target Trimmed from $553 to $543
6d ago
MDGL: Rezdiffra’s Strong Q2 Momentum, Robust Cash Position, and Expanding MASH Market Penetration Underpin TD Cowen Buy Rating
Premium
Ratings
MDGL: Rezdiffra’s Strong Q2 Momentum, Robust Cash Position, and Expanding MASH Market Penetration Underpin TD Cowen Buy Rating
6d ago
Madrigal Pharmaceuticals reports Q2 EPS ($1.99), consensus ($2.23)
Premium
The Fly
Madrigal Pharmaceuticals reports Q2 EPS ($1.99), consensus ($2.23)
7d ago
Madrigal Pharmaceuticals price target raised to $739 from $737 at Citizens
PremiumThe FlyMadrigal Pharmaceuticals price target raised to $739 from $737 at Citizens
20d ago
Madrigal Pharmaceuticals announces three new resmetirom patents
Premium
The Fly
Madrigal Pharmaceuticals announces three new resmetirom patents
24d ago
Madrigal Shareholders Approve 2026 Equity Compensation Plans
Premium
Company Announcements
Madrigal Shareholders Approve 2026 Equity Compensation Plans
2M ago
Madrigal’s Rezdiffra Drives Blockbuster Growth Amid Costs
PremiumCompany AnnouncementsMadrigal’s Rezdiffra Drives Blockbuster Growth Amid Costs
3M ago
Paulson takes new stake in Amicus, cuts position in Madrigal Pharma
Premium
The Fly
Paulson takes new stake in Amicus, cuts position in Madrigal Pharma
3M ago
Madrigal Pharmaceuticals price target raised to $709 from $640 at Truist
Premium
The Fly
Madrigal Pharmaceuticals price target raised to $709 from $640 at Truist
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100